Menu Search
Equities

Acumen Pharmaceuticals Inc

ABOS:NSQ

Acumen Pharmaceuticals Inc

Actions
  • Price (USD)2.53
  • Today's Change-0.145 / -5.42%
  • Shares traded182.30k
  • 1 Year change+24.63%
  • Beta0.0105
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Acumen Pharmaceuticals Inc's net income fell 22.20% from a loss of 42.86m to a larger loss of 52.37m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-27.82%
Return on equity-31.42%
Return on investment-29.32%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Acumen Pharmaceuticals Inc fell by 62.98m. Cash Flow from Financing totalled 151.75m or -- of revenues. In addition the company used 43.06m for operations while cash used for investing totalled 171.67m.
Cash flow per share-1.12
Price/Cash flow per share--
Book value per share4.06
Tangible book value per share4.06
More ▼

Balance sheet in USDView more

Acumen Pharmaceuticals Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.42% of the market capitalization can be attributed to its 66.89m and debt could be paid in full if management chose.
Current ratio17.37
Quick ratio--
Total debt/total equity0.1204
Total debt/total capital0.1075
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.